{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%2BG-CSF", "query": { "intervention": "Placebo +G-CSF" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%2BG-CSF&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T14:57:15.106Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01933932", "title": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pegylated G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 510, "start_date": "2013-09-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 17, "location_summary": "Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933932" }, { "nct_id": "NCT00004132", "title": "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Oral Complications", "Radiation Toxicity" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004132" }, { "nct_id": "NCT03197935", "title": "A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2017-07-24", "completion_date": "2022-09-28", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 12, "location_summary": "Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Carrollton", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03197935" }, { "nct_id": "NCT04447469", "title": "Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID" ], "interventions": [ { "name": "mavrilimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kiniksa Pharmaceuticals International, plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 814, "start_date": "2020-07-28", "completion_date": "2022-01-14", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 9, "location_summary": "Los Angeles, California • San Diego, California • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447469" }, { "nct_id": "NCT02703051", "title": "A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "GMI-1271", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Placebo Injection", "type": "DRUG" }, { "name": "Placebo Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlycoMimetics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "19 Years to 60 Years" }, "enrollment_count": 54, "start_date": "2015-11", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02703051" }, { "nct_id": "NCT00103662", "title": "Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Granulocyte colony-stimulating factor plus plerixafor", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor plus placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 302, "start_date": "2005-01", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2014-03-13", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103662" }, { "nct_id": "NCT03407430", "title": "Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Lymphoma", "Pain" ], "interventions": [ { "name": "Pregabalin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 11, "start_date": "2016-01-27", "completion_date": "2017-07-20", "has_results": true, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407430" }, { "nct_id": "NCT00300053", "title": "ACT34-CMI -- Adult Autologous CD34+ Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myocardial Ischemia" ], "interventions": [ { "name": "CLBS14 (low-dose)", "type": "BIOLOGICAL" }, { "name": "CLBS14 (high-dose)", "type": "BIOLOGICAL" }, { "name": "placebo injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 321, "start_date": "2006-04", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300053" }, { "nct_id": "NCT04211259", "title": "Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Loratadine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-04-18", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04211259" }, { "nct_id": "NCT00046930", "title": "Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "zosuquidar trihydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 449, "start_date": "2002-09-17", "completion_date": null, "has_results": true, "last_update_posted_date": "2023-07-05", "last_synced_at": "2026-09-10T14:57:15.106Z", "location_count": 91, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046930" } ] }